Conditions: Metastatic Renal Cell Carcinoma; Advanced Urothelial Carcinoma; Advanced Gastric Adenocarcinoma; Metastatic Colorectal Adenocarcinoma
Interventions: Drug: Ibrutinib; Drug: Everolimus; Drug: Docetaxel; Drug: Paclitaxel; Drug: Cetuximab; Drug: Pembrolizumab
Sponsor: Pharmacyclics LLC.
**RECRUITING NOW**
Interventions: Drug: Ibrutinib; Drug: Everolimus; Drug: Docetaxel; Drug: Paclitaxel; Drug: Cetuximab; Drug: Pembrolizumab
Sponsor: Pharmacyclics LLC.
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
